{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:54:44Z","timestamp":1792652084004,"version":"4.5.0"},"reference-count":60,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,13]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Initial clinical trials with drugs targeting epigenetic modulators, such as bromodomain and extraterminal protein (BET) inhibitors, demonstrate modest results in acute myeloid leukemia (AML). A major reason for this involves an increased transcriptional plasticity within AML, which allows the cells to escape therapeutic pressure. In this study, we investigated the immediate epigenetic and transcriptional responses after BET inhibition and demonstrated that BET inhibitor\u2013mediated release of bromodomain-containing protein 4 from chromatin is accompanied by acute compensatory feedback that attenuates downregulation or even increases the expression of specific transcriptional modules. This adaptation is marked at key AML maintenance genes and is mediated by p300, suggesting a rational therapeutic opportunity to improve outcomes by combining BET and p300 inhibition. p300 activity is required during all steps of resistance adaptation; however, the specific transcriptional programs that p300 regulates to induce resistance to BET inhibition differ, in part, between AML subtypes. As a consequence, in some AMLs, the requirement for p300 is highest during the earlier stages of resistance to BET inhibition, when p300 regulates transitional transcriptional patterns that allow leukemia-homeostatic adjustments. In other AMLs, p300 shapes a linear resistance to BET inhibition and remains critical throughout all stages of the evolution of resistance. Altogether, our study elucidates the mechanisms that underlie an \u201cacute\u201d state of resistance to BET inhibition, achieved through p300 activity, and how these mechanisms remodel to mediate \u201cchronic\u201d resistance. Importantly, our data also suggest that sequential treatment with BET and p300 inhibition may prevent resistance development, thereby improving outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2022019306","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T08:53:56Z","timestamp":1733734436000},"page":"748-764","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":25,"title":["Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-8121","authenticated-orcid":false,"given":"Viral","family":"Shah","sequence":"first","affiliation":[{"name":"1Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"2University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"3German Cancer Consortium, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1390-6592","authenticated-orcid":false,"given":"George","family":"Giotopoulos","sequence":"additional","affiliation":[{"name":"4Cambridge Stem Cell Institute, Cambridge, United Kingdom"},{"name":"5Department of Haematology, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikari","family":"Osaki","sequence":"additional","affiliation":[{"name":"4Cambridge Stem Cell Institute, Cambridge, United Kingdom"},{"name":"5Department of Haematology, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Meyerh\u00f6fer","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"2University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"3German Cancer Consortium, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshwar","family":"Meduri","sequence":"additional","affiliation":[{"name":"4Cambridge Stem Cell Institute, Cambridge, United Kingdom"},{"name":"5Department of Haematology, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9758-6633","authenticated-orcid":false,"given":"Aaron","family":"Gallego-Crespo","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"2University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"3German Cancer Consortium, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1011-5919","authenticated-orcid":false,"given":"Malte A.","family":"Behrendt","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"2University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"3German Cancer Consortium, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Saura-Pa\u00f1ella","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"2University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"3German Cancer Consortium, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti","family":"Tarkar","sequence":"additional","affiliation":[{"name":"6GlaxoSmithKline Research and Development, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedict","family":"Schubert","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"2University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"3German Cancer Consortium, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8714-205X","authenticated-orcid":false,"given":"Haiyang","family":"Yun","sequence":"additional","affiliation":[{"name":"4Cambridge Stem Cell Institute, Cambridge, United Kingdom"},{"name":"5Department of Haematology, University of Cambridge, Cambridge, United Kingdom"},{"name":"7Department of Medicine V, Hematology, Oncology, and Rheumatology, University of Heidelberg, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8418-5783","authenticated-orcid":false,"given":"Sarah J.","family":"Horton","sequence":"additional","affiliation":[{"name":"4Cambridge Stem Cell Institute, Cambridge, United Kingdom"},{"name":"5Department of Haematology, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8632-4556","authenticated-orcid":false,"given":"Shuchi","family":"Agrawal-Singh","sequence":"additional","affiliation":[{"name":"4Cambridge Stem Cell Institute, Cambridge, United Kingdom"},{"name":"5Department of Haematology, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia S.","family":"Haehnel","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"2University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"3German Cancer Consortium, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Basheer","sequence":"additional","affiliation":[{"name":"4Cambridge Stem Cell Institute, Cambridge, United Kingdom"},{"name":"5Department of Haematology, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Lugo","sequence":"additional","affiliation":[{"name":"8Adaptive Immunity and Immuno-epigenetics Research Unit, GlaxoSmithKline Research and Development, Stevenage, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0278-1061","authenticated-orcid":false,"given":"Ioanna","family":"Eleftheriadou","sequence":"additional","affiliation":[{"name":"6GlaxoSmithKline Research and Development, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Barbash","sequence":"additional","affiliation":[{"name":"6GlaxoSmithKline Research and Development, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-0877","authenticated-orcid":false,"given":"Arindam","family":"Dhar","sequence":"additional","affiliation":[{"name":"6GlaxoSmithKline Research and Development, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W. M.","family":"K\u00fchn","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"2University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"3German Cancer Consortium, Mainz, Germany"},{"name":"9Research Center for Immunotherapy, University Medical Center, University of Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borhane","family":"Guezguez","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"2University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"3German Cancer Consortium, Mainz, Germany"},{"name":"9Research Center for Immunotherapy, University Medical Center, University of Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Theobald","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"2University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"3German Cancer Consortium, Mainz, Germany"},{"name":"9Research Center for Immunotherapy, University Medical Center, University of Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0383-0507","authenticated-orcid":false,"given":"Thomas","family":"Kindler","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"2University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"3German Cancer Consortium, Mainz, Germany"},{"name":"9Research Center for Immunotherapy, University Medical Center, University of Mainz, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gallipoli","sequence":"additional","affiliation":[{"name":"10Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4172-3614","authenticated-orcid":false,"given":"Paul","family":"Yeh","sequence":"additional","affiliation":[{"name":"11Monash Haematology, Monash Health and School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-5029","authenticated-orcid":false,"given":"Mark A.","family":"Dawson","sequence":"additional","affiliation":[{"name":"12Department of Clinical Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2666-3326","authenticated-orcid":false,"given":"Rab K.","family":"Prinjha","sequence":"additional","affiliation":[{"name":"8Adaptive Immunity and Immuno-epigenetics Research Unit, GlaxoSmithKline Research and Development, Stevenage, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0312-161X","authenticated-orcid":false,"given":"Brian J. P.","family":"Huntly","sequence":"additional","affiliation":[{"name":"4Cambridge Stem Cell Institute, Cambridge, United Kingdom"},{"name":"5Department of Haematology, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0330-7959","authenticated-orcid":false,"given":"Daniel","family":"Sasca","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Oncology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"2University Cancer Center, University Medical Center of the Johannes Gutenberg University, Mainz, Germany"},{"name":"3German Cancer Consortium, Mainz, Germany"},{"name":"9Research Center for Immunotherapy, University Medical Center, University of Mainz, Mainz, Germany"},{"name":"13Institute for Quantitative and Computational Biosciences, Johannes Gutenberg University, Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2025100209412380100_bib1","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1182\/blood-2016-10-696054","article-title":"Biology and relevance of human acute myeloid leukemia stem cells","volume":"129","author":"Thomas","year":"2017","journal-title":"Blood"},{"issue":"23","key":"2025100209412380100_bib2","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025100209412380100_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41588-018-0270-1","article-title":"Subtype-specific regulatory network rewiring in acute myeloid leukemia","volume":"51","author":"Assi","year":"2019","journal-title":"Nat Genet"},{"issue":"10","key":"2025100209412380100_bib4","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41588-021-00925-9","article-title":"Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression","volume":"53","author":"Yun","year":"2021","journal-title":"Nat Genet"},{"issue":"11","key":"2025100209412380100_bib5","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7370","key":"2025100209412380100_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"issue":"7","key":"2025100209412380100_bib7","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMra1112635","article-title":"Targeting epigenetic readers in cancer","volume":"367","author":"Dawson","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"7370","key":"2025100209412380100_bib8","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"issue":"4","key":"2025100209412380100_bib9","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.molcel.2005.06.027","article-title":"The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription","volume":"19","author":"Jang","year":"2005","journal-title":"Mol Cell"},{"issue":"1","key":"2025100209412380100_bib10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cell.2009.05.047","article-title":"Control of inducible gene expression by signal-dependent transcriptional elongation","volume":"138","author":"Hargreaves","year":"2009","journal-title":"Cell"},{"issue":"1","key":"2025100209412380100_bib11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.molcel.2017.06.004","article-title":"BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment","volume":"67","author":"Winter","year":"2017","journal-title":"Mol Cell"},{"issue":"12","key":"2025100209412380100_bib12","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/nsmb.2912","article-title":"BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones","volume":"21","author":"Kanno","year":"2014","journal-title":"Nat Struct Mol Biol"},{"issue":"2","key":"2025100209412380100_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/leu.2013.338","article-title":"Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia","volume":"28","author":"Dawson","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"2025100209412380100_bib14","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1038\/s41467-019-10652-9","article-title":"Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia","volume":"10","author":"Bell","year":"2019","journal-title":"Nat Commun"},{"issue":"7570","key":"2025100209412380100_bib15","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature14888","article-title":"BET inhibitor resistance emerges from leukaemia stem cells","volume":"525","author":"Fong","year":"2015","journal-title":"Nature"},{"issue":"7570","key":"2025100209412380100_bib16","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature14898","article-title":"Transcriptional plasticity promotes primary and acquired resistance to BET inhibition","volume":"525","author":"Rathert","year":"2015","journal-title":"Nature"},{"issue":"6","key":"2025100209412380100_bib17","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/ijc.33861","article-title":"Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: results of a phase I\/II open-label, dose escalation study","volume":"150","author":"Cousin","year":"2022","journal-title":"Int J Cancer"},{"issue":"4","key":"2025100209412380100_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1078-0432.CCR-22-1284","article-title":"A\u00a0phase I\/II open-label study of molibresib for the treatment of relapsed\/refractory hematologic malignancies","volume":"29","author":"Dawson","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2025100209412380100_bib19","doi-asserted-by":"crossref","first-page":"e20200924","DOI":"10.1084\/jem.20200924","article-title":"Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia","volume":"218","author":"Stuani","year":"2021","journal-title":"J\u00a0Exp Med"},{"key":"2025100209412380100_bib20","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/2159-8290.CD-19-1469","article-title":"Leukemia cell of origin influences apoptotic priming and sensitivity to lsd1 inhibition","volume":"10","author":"Cai","year":"2020","journal-title":"Cancer Discov"},{"issue":"1","key":"2025100209412380100_bib21","doi-asserted-by":"crossref","first-page":"P186","DOI":"10.1016\/j.cell.2018.08.058","article-title":"Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors","volume":"175","author":"Huang","year":"2018","journal-title":"Cell"},{"issue":"1","key":"2025100209412380100_bib22","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41467-020-14604-6","article-title":"A\u00a0combination strategy targeting enhancer plasticity exerts synergistic lethality against BETi-resistant leukemia cells","volume":"11","author":"Guo","year":"2020","journal-title":"Nat Commun"},{"issue":"15","key":"2025100209412380100_bib23","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood.2019002922","article-title":"Mechanistic basis and efficacy of targeting \u03b2-catenin-TCF7L2-JMJD6-MYC axis to overcome resistance to BET inhibitors","volume":"135","author":"Saenz","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2025100209412380100_bib24","doi-asserted-by":"crossref","first-page":"P483","DOI":"10.1016\/j.ccell.2018.08.007","article-title":"Identification of chemotherapy-induced leukemic-regenerating cells reveals a transient vulnerability of human AML recurrence","volume":"34","author":"Boyd","year":"2018","journal-title":"Cancer Cell"},{"issue":"7661","key":"2025100209412380100_bib25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nature22993","article-title":"Tracing the origins of relapse in acute myeloid leukaemia to stem cells","volume":"547","author":"Shlush","year":"2017","journal-title":"Nature"},{"issue":"8","key":"2025100209412380100_bib27","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nm1443","article-title":"A\u00a0previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis","volume":"12","author":"Yan","year":"2006","journal-title":"Nat Med"},{"issue":"6","key":"2025100209412380100_bib28","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.celrep.2013.08.020","article-title":"Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1","volume":"4","author":"Ben-Ami","year":"2013","journal-title":"Cell Rep"},{"issue":"2","key":"2025100209412380100_bib29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-626671","article-title":"Genome-wide studies identify a novel interplay between AML1 and AML1\/ETO in t(8;21) acute myeloid leukemia","volume":"127","author":"Li","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2025100209412380100_bib30","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.celrep.2014.08.024","article-title":"Identification of a dynamic core transcriptional network in t(8;21) AML that regulates differentiation block and self-renewal","volume":"8","author":"Ptasinska","year":"2014","journal-title":"Cell Rep"},{"issue":"9","key":"2025100209412380100_bib31","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1172\/JCI68557","article-title":"Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells","volume":"123","author":"Goyama","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"2025100209412380100_bib32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-981-10-3233-2_11","article-title":"RUNX1-ETO leukemia","volume":"962","author":"Lin","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"7460","key":"2025100209412380100_bib33","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature12287","article-title":"A\u00a0stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis","volume":"500","author":"Sun","year":"2013","journal-title":"Nature"},{"issue":"1","key":"2025100209412380100_bib34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cell.2018.04.033","article-title":"Time-resolved analysis reveals rapid dynamics and broad scope of the CBP\/p300 acetylome","volume":"174","author":"Weinert","year":"2018","journal-title":"Cell"},{"issue":"6043","key":"2025100209412380100_bib35","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1126\/science.1201662","article-title":"The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation","volume":"333","author":"Wang","year":"2011","journal-title":"Science"},{"issue":"15","key":"2025100209412380100_bib36","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2011-10-386086","article-title":"Chromatin accessibility, p300, and histone acetylation define PML-RAR\u03b1 and AML1-ETO binding sites in acute myeloid leukemia","volume":"120","author":"Saeed","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2025100209412380100_bib37","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.molcel.2015.04.011","article-title":"BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia","volume":"58","author":"Roe","year":"2015","journal-title":"Mol Cell"},{"issue":"6390","key":"2025100209412380100_bib38","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1126\/science.aao2793","article-title":"SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis","volume":"360","author":"Muhar","year":"2018","journal-title":"Science"},{"issue":"4","key":"2025100209412380100_bib39","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.chembiol.2020.12.004","article-title":"Targeted degradation of the enhancer lysine acetyltransferases CBP and p300","volume":"28","author":"Vannam","year":"2021","journal-title":"Cell Chem Biol"},{"issue":"15","key":"2025100209412380100_bib42","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"SynergyFinder: a web application for analyzing drug combination dose-response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics"},{"issue":"9","key":"2025100209412380100_bib43","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/leu.2013.77","article-title":"A\u00a0powerful molecular synergy between mutant nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice","volume":"27","author":"Mupo","year":"2013","journal-title":"Leukemia"},{"key":"2025100209412380100_bib44","doi-asserted-by":"crossref","first-page":"110156","DOI":"10.1016\/j.biopha.2020.110156","article-title":"Roles of S100 family members in drug resistance in tumors: status and prospects","volume":"127","author":"Hua","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"2025100209412380100_bib45","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/leu.2011.388","article-title":"Elevated S100A8\/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia","volume":"26","author":"Spijkers-Hagelstein","year":"2012","journal-title":"Leukemia"},{"issue":"10","key":"2025100209412380100_bib46","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1038\/s41375-019-0504-y","article-title":"Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML","volume":"33","author":"Karjalainen","year":"2019","journal-title":"Leukemia"},{"issue":"21","key":"2025100209412380100_bib47","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2018-12-889725","article-title":"NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML","volume":"133","author":"Sasca","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2025100209412380100_bib48","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.leukres.2013.05.002","article-title":"CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21)","volume":"37","author":"Iriyama","year":"2013","journal-title":"Leuk Res"},{"issue":"8","key":"2025100209412380100_bib49","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/sj.leu.2402174","article-title":"CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical\u00a0prognosis","volume":"15","author":"Raspadori","year":"2001","journal-title":"Leukemia"},{"issue":"12","key":"2025100209412380100_bib50","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-020-1089-8","article-title":"Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial","volume":"26","author":"Burd","year":"2020","journal-title":"Nat Med"},{"issue":"2","key":"2025100209412380100_bib51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"issue":"8","key":"2025100209412380100_bib52","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1200\/JCO.21.01548","article-title":"Response rate, event-free survival, and overall survival in newly diagnosed acute myeloid leukemia: US Food and Drug Administration trial-level and patient-level analyses","volume":"40","author":"Norsworthy","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2025100209412380100_bib53","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2025100209412380100_bib54","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41591-019-0376-8","article-title":"Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer","volume":"25","author":"Mohammad","year":"2019","journal-title":"Nat Med"},{"issue":"7","key":"2025100209412380100_bib55","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1056\/NEJMra1805035","article-title":"Epigenetic therapies for cancer","volume":"383","author":"Bates","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2025100209412380100_bib56","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41416-019-0648-6","article-title":"Principles and mechanisms of non-genetic resistance in cancer","volume":"122","author":"Bell","year":"2020","journal-title":"Br J Cancer"},{"issue":"7","key":"2025100209412380100_bib57","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ccell.2021.06.003","article-title":"The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance","volume":"39","author":"Joshi","year":"2021","journal-title":"Cancer Cell"},{"issue":"8","key":"2025100209412380100_bib58","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1038\/leu.2012.49","article-title":"Depletion of RUNX1\/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding","volume":"26","author":"Ptasinska","year":"2012","journal-title":"Leukemia"},{"issue":"7674","key":"2025100209412380100_bib40","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nature24028","article-title":"Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours","volume":"550","author":"Lasko","year":"2017","journal-title":"Nature"},{"issue":"13","key":"2025100209412380100_bib59","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1101\/gad.14.13.1553","article-title":"CBP\/p300 in cell growth, transformation, and development","volume":"14","author":"Goodman","year":"2000","journal-title":"Genes Dev"},{"issue":"7180","key":"2025100209412380100_bib60","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nature06546","article-title":"The structural basis of protein acetylation by the p300\/CBP transcriptional coactivator","volume":"451","author":"Liu","year":"2008","journal-title":"Nature"},{"issue":"6","key":"2025100209412380100_bib61","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood-2007-02-074203","article-title":"Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression","volume":"110","author":"Gattenloehner","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2025100209412380100_bib62","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1158\/2159-8290.CD-21-0956","article-title":"Unleashing cell-intrinsic inflammation as a strategy to kill AML blasts","volume":"12","author":"Ellegast","year":"2022","journal-title":"Cancer Discov"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/7\/748\/2355588\/blood_bld-2022-019306r1-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/7\/748\/2355588\/blood_bld-2022-019306r1-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:41:34Z","timestamp":1759412494000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/7\/748\/534395\/Acute-resistance-to-BET-inhibitors-remodels"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,2,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022019306","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2,13]]},"published":{"date-parts":[[2025,2,13]]}}}